Repare Therapeutics To Host Webcast To Report Data From The Lunresertib And Camonsertib Combination Phase 1 MYTHIC Clinical Trial On Thursday, December 12 At 4:30 P.m. ET
Repare Therapeutics To Host Webcast To Report Data From The Lunresertib And Camonsertib Combination Phase 1 MYTHIC Clinical Trial On Thursday, December 12 At 4:30 P.m. ET
Event to be webcast live on Thursday, December 12 at 4:30 p.m. ET
活動將於12月12日星期四下午4:30（東部時間）現場直播
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib in combination with camonsertib at the recommended Phase 2 dose in an expansion cohort in patients with platinum-resistant ovarian and endometrial cancers harboring CCNE1 amplification or FBXW7 or PPP2R1A mutations, on Thursday, December 12, 2024 at 4:30 p.m. Eastern Time. Repare's executive management team will be joined by Brian Slomovitz, M.D., Director of Gynecologic Oncology at Mount Sinai Medical Center.
Repare Therapeutics Inc.（"Repare"或"公司"）（納斯達克:RPTX），一家領先的臨床階段精準腫瘤學公司，今天宣佈將於2024年12月12日星期四下午4:30（東部時間）召開電話會議和現場直播，展示其正在進行的第一階段MYTHIC臨床試驗的最新數據，該試驗評估lunresertib與camonsertib聯合在具有CCNE1擴增或FBXW7或PPP2R1A突變的鉑耐藥卵巢癌和子宮內膜癌患者中推薦的第二階段劑量的療效。Repare的執行管理團隊將與Mount Sinai 醫療中心婦科腫瘤學董事Brian Slomovitz萬.D.共同出席。
譯文內容由第三人軟體翻譯。
